Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TacroBell SR vs TacroBell in Renal Transplant Maintenance
NCT04224350Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplant rejection (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Incidence of composite efficacy failure (biopsy-confirmed acute rejection; TCMR, graft loss, death, or follow-up failure) at 24 weeks. Status: unknown.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04224350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224350.